Nivalin (Galantamine Hydrobromide)

Galantamine, the active ingredient in Nivalin, is an acetylcholinesterase inhibitor presented as a sterile injectable solution for intramuscular, intravenous, and subcutaneous use. It is indicated for the treatment of mild to moderate Alzheimer’s disease and related dementia in adult patients.

GNH USA supplies Nivalin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions. Our global network ensures timely delivery and reliable supply chain management.

Galantamine is used in the management of cognitive decline associated with Alzheimer’s disease and related dementias.

Alzheimer’s disease: improves cognition, memory, and daily functional abilities, aiding patients in performing routine tasks. Mild to moderate dementia: supports attention, memory retention, and overall mental clarity, contributing to better quality of life. Cognitive decline in Alzheimer’s: helps stabilize disease progression and may delay worsening of symptoms.

Galantamine may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: upset stomach often occurring shortly after dosing. - Vomiting: may accompany nausea or occur independently. - Diarrhea: loose stools that can lead to dehydration if severe. - Dizziness: sensation of light‑headedness, especially when standing quickly.

Serious or Rare Side Effects: - Severe bradycardia: markedly slow heart rate requiring medical attention. - Liver toxicity: elevated liver enzymes or hepatitis signs. - Seizures: rare convulsive episodes that need immediate care.

When prescribing galantamine, clinicians should consider several safety aspects.

Renal impairment: adjust monitoring and consider dose modification. Hepatic disease: use with caution and monitor liver function tests. Cardiac conduction disorders: observe ECG for bradyarrhythmias. Concurrent cholinergic drugs: assess for additive cholinergic effects. Pregnancy and lactation: safety not established; weigh risks versus benefits. Store at room temperature: keep in original container, protect from moisture and light.

Galantamine interacts with several drug classes that may alter its efficacy or safety.

Major Interactions (Avoid): - Anticholinergic agents: diminish therapeutic effect of galantamine. - Beta‑blockers: increase risk of bradycardia and heart block. - CYP2D6 inhibitors (e.g., quinidine, fluoxetine): raise galantamine plasma levels.

Moderate Interactions (Monitor Closely): - Other cholinesterase inhibitors: additive cholinergic toxicity. - Central nervous system depressants: may enhance dizziness and sedation.